February 2, 2009 / 7:04 AM / 11 years ago

Astellas: not mulling hostile CV Therapeutics bid

TOKYO, Feb 2 (Reuters) - Astellas Pharma Inc (4503.T), Japan’s second-largest drugmaker, said on Monday it was not considering a hostile bid for CV Therapeutics Inc CVTX.O and its offer price was the best one.

Astellas last week said it had offered to buy all shares in CV Therapeutics, a U.S. biotechnology firm, for $16 each or $1 billion in total. [ID:nN27436060]

CV Therapeutics, which had already rejected the offer, announced later the extension of a shareholder rights plan to counter Astellas’ bid. [ID:nBNG379272] (Reporting by Yumiko Nishitani)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below